Eli Lilly’s blockbuster drug, Mounjaro, has officially made its way to India, marking a significant milestone in the country’s healthcare landscape. As of March 20, 2025, this revolutionary once-a-week injection is now available at a price of 4,375 rupees per 5mg dose. This translates to a monthly cost ranging between 14,000 and 17,500 rupees—significantly lower than the staggering $1,000 per month price tag in the United States.
A Game-Changer in Diabetes and Weight Management
Mounjaro, known for its effectiveness in treating type 2 diabetes and promoting weight loss, works by targeting both GIP and GLP-1 receptors. This dual-action mechanism helps control blood sugar levels while also suppressing appetite, making it a highly sought-after option for patients struggling with obesity and diabetes.
Booming Demand and Growing Competition
The global demand for weight-loss medications has surged, and India is no exception. With the market projected to reach a staggering $150 billion over the next decade, pharmaceutical companies are racing to secure their share. Indian pharma giants such as Sun Pharma, Cipla, and Lupin are among those exploring the development of generic versions of these medications, aiming to provide more affordable alternatives to patients.
The Road Ahead
Despite its relatively high cost, Mounjaro's arrival in India is expected to transform diabetes and weight management treatments. With increased competition and the potential for locally manufactured generics, accessibility and affordability may improve in the coming years. As pharmaceutical advancements continue, India is poised to play a crucial role in shaping the future of weight-loss and diabetes care on a global scale.
